Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2021

Open Access 01-12-2021 | Esophageal Cancer | Review

Recent advances of m6A methylation modification in esophageal squamous cell carcinoma

Authors: Xiaoqing Zhang, Ning Lu, Li Wang, Yixuan Wang, Minna Li, Ying Zhou, Manli Cui, Mingxin Zhang, Lingmin Zhang

Published in: Cancer Cell International | Issue 1/2021

Login to get access

Abstract

In recent years, with the development of RNA sequencing technology and bioinformatics methods, the epigenetic modification of RNA based on N6-methyladenosine (m6A) has gradually become a research hotspot in the field of bioscience. m6A is the most abundant internal modification in eukaryotic messenger RNAs (mRNAs). m6A methylation modification can dynamically and reversibly regulate RNA transport, localization, translation and degradation through the interaction of methyltransferase, demethylase and reading protein. m6A methylation can regulate the expression of proto-oncogenes and tumor suppressor genes at the epigenetic modification level to affect tumor occurrence and metastasis. The morbidity and mortality of esophageal cancer (EC) are still high worldwide. Esophageal squamous cell carcinoma (ESCC) is the most common tissue subtype of EC. This article reviews the related concepts, biological functions and recent advances of m6A methylation in ESCC, and looks forward to the prospect of m6A methylation as a new diagnostic biomarker and potential therapeutic target for ESCC.
Literature
1.
Abnet CC, et al. Epidemiology of esophageal squamous cell carcinoma. Gastroenterology. 2018;154:360–73.PubMedCrossRef
2.
3.
Cheung WY, et al. Genetic variations in esophageal cancer risk and prognosis. Gastroenterol Clin North Am. 2009;38:75–91.PubMedCrossRef
4.
Hassanabad AF, Chehade R, Breadner D, Raphael J. Esophageal carcinoma: towards targeted therapies. Cell Oncol. 2020;43(2):195–209.CrossRef
5.
van Rossum PSN, Mohammad NH, Vleggaar FP, van Hillegersberg R. Treatment for unresectable or metastatic oesophageal cancer: current evidence and trends. Nat Rev Gastroenterol Hepatol. 2018;15:235–49.PubMedCrossRef
6.
Abbas G, Krasna M. Overview of esophageal cancer. Ann Car-diothorac Surg. 2017;6(2):131.CrossRef
7.
Zhao Y, Shi Y, Shen H, Xie W. m6A-binding proteins: the emerging crucial performers in epigenetics. Hematol Oncol. 2020;13:35.CrossRef
8.
Kane SE, Beemon K. Precise localization of m6A in Rous sarcoma virus RNA reveals clustering of methylation sites: Implications for RNA processing. Mol Cell Biol. 1985;5(9):2298–306.PubMedPubMedCentral
9.
10.
Bokar JA, et al. Purification and cDNA cloning of the AdoMet-binding subunit of the human mRNA (N6-adenosine)-methyltransferase. RNA. 1997;3(11):1233–47.PubMedPubMedCentral
11.
Zhang S. Mechanism of N(6)-methyladenosine modification and its emerging role in cancer. Pharmacol Ther. 2018;189:173–83.PubMedCrossRef
12.
13.
14.
15.
Wang X, Lu Z, Gomez A, et al. N-6-methyladenosine -dependent regulation of messenger RNA stability. Nature. 2014;505(7481):117–20.PubMedCrossRef
16.
Parashar NC, Parashar G, Nayyar H, et al. N6-adenine DNA methylation demystified in eukaryotic genome: From biology to pathology. Biochimie. 2018;144:56–62.PubMedCrossRef
17.
Edupuganti RR, Geiger S, Lindeboom RGH, et al. N- 6-methyladenosine (m6A) recruits and repels proteins to regulate mRNA homeostasis. Nat Struct Mol Biol. 2017;24(10):870.PubMedPubMedCentralCrossRef
18.
Wang Y, Li Y, Toth JI, et al. N6- methyladenosine modification destabilizes developmental regulators in embryonic stem cells. Nat Cell Biol. 2014;16(2):191–8.PubMedPubMedCentralCrossRef
19.
20.
Zheng G, Dahl JA, Niu Y, et al. ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility. Mol Cell. 2013;49(1):18–29.PubMedCrossRef
21.
22.
Gerken T, Girard CA, Tung YC, et al. The obesity-associated FTO gene encodes a 2-oxoglutarate-dependent nucleic acid demethylase. Science. 2007;318(5855):1469–72.PubMedPubMedCentralCrossRef
23.
Cardelli M, Marchegiani F, Cavallone L, et al. A polymorphism of the YTHDF2 gene (1p35) located in an Alu-rich genomic domain is associated with human longevity. J Gerontol A Biol Sci Med Sci. 2006;61(6):547–56.PubMedCrossRef
24.
Huang H, Weng H, Sun W, et al. Recognition of RNA N6-methyladenosine by IGF2BP proteins enhances mRNA stability and translation. Nat Cell Biol. 2018;20(3):285–95.PubMedPubMedCentralCrossRef
25.
26.
Xiao Y, Xue J, Zhang L, et al. Misalignment fault diagnosis for wind turbines based on information fusion. Entropy (Basel). 2021;23(2):243.CrossRef
27.
Nagaki Y, Motoyama S, Yamaguchi T, et al. m(6)A demethylase ALKBH5 promotes proliferation of esophageal squamous cell carcinoma associated with poor prognosis. Genes Cells. 2020;25(8):547–61.PubMedCrossRef
28.
Xue J, Xiao P, Yu X, Zhang X. A positive feedback loop between AlkB homolog 5 and miR-193a-3p promotes growth and metastasis in esophageal squamous cell carcinoma. Hum Cell. 2021;34(2):502–14.PubMedCrossRef
29.
Yang N, Ying P, Tian J, et al. Genetic variants in m6A modification genes are associated with esophageal squamous-cell carcinoma in the Chinese population. Carcinogenesis. 2020;41(6):761–8.PubMedCrossRef
30.
Xia TL, Li X, Wang X, et al. Upregulation of METTL3 expression predicts poor prognosis in patients with esophageal squamous cell carcinoma. Cancer Manag Res. 2020;12:5729–37.PubMedPubMedCentralCrossRef
31.
32.
Liu S, Huang M, Chen Z, et al. FTO promotes cell proliferation and migration in esophageal squamous cell carcinoma through up-regulation of MMP13. Exp Cell Res. 2020;389(1):111894.PubMedCrossRef
33.
Guo H, Wang B, Xu K, et al. m6A reader HNRNPA2B1 promotes esophageal cancer progression via up-regulation of ACLY and ACC1. Front Oncol. 2020;10:553045.PubMedPubMedCentralCrossRef
34.
Xu LC, Pan JX, Pan HD. Construction and validation of an m6A RNA methylation regulators-based prognostic signature for esophageal cancer. Cancer Manag Res. 2020;12:5385–94.PubMedPubMedCentralCrossRef
35.
Pourhanifeh MH, Vosough M, Mahjoubin-Tehran M, et al. Autophagy-related microRNAs: possible regulatory roles and therapeutic potential in and gastrointestinal cancers. Pharmacol Res. 2020;161:105133.PubMedCrossRef
36.
Jamali L, Tofigh R, Tutunchi S, et al. Circulating microRNAs as diagnostic and therapeutic biomarkers in gastric and esophageal cancers. J Cell Physiol. 2018;233(11):8538–50.PubMedCrossRef
37.
Naeli P, Pourhanifeh MH, Karimzadeh MR, et al. Circular RNAs and gastrointestinal cancers: epigenetic regulators with a prognostic and therapeutic role. Crit Rev Oncol Hematol. 2020;145:102854.PubMedCrossRef
38.
Hesari A, Azizian M, Sheikhi A, et al. Chemopreventive and therapeutic potential of curcumin in esophageal cancer: current and future status. Int J Cancer. 2019;144(6):1215–26.PubMedCrossRef
39.
Sarvizadeh M, Hasanpour O, Naderi Ghale-Noie Z, et al. Allicin and digestive system cancers: from chemical structure to its therapeutic opportunities. Front Oncol. 2021;11:650256.PubMedPubMedCentralCrossRef
40.
Xu LC, Pan JX, Pan HD. Construction and validation of an m6A RNA methylation regulators-based prognostic signature for esophageal cancer. Cancer Manag Res. 2020;6(12):5385–94.CrossRef
41.
Liu X, Gonzalez G, Dai X, et al. Adenylate kinase 4 modulates the resistance of breast cancer cells to tamoxifen through an m6A-based epitranscriptomic mechanism. Mol Ther. 2020;28(12):2593–604.PubMedCrossRefPubMedCentral
42.
Zhang CZ, Samanta D, Lu HQ, et al. Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated m6A-demethylation of NANOG mRNA. PNAS. 2016;113(14):E2047–56.PubMedPubMedCentralCrossRef
43.
Hao L, Wang JM, Liu BQ, et al. m6A-YTHDF1-mediated TRIM29 upregulation facilitates the stem cell-like phenotype of cisplatin-resistant ovarian cancer cells. Biochim Biophys Acta Mol Cell Res. 2021;1868:118878.PubMedCrossRef
44.
Fukumoto T, Zhu H, Nacarelli T, et al. N(6)-methylation of adenosine of FZD10 mRNA contributes to PARP inhibitor resistance. Cancer Res. 2019;79:2812–20.PubMedPubMedCentralCrossRef
45.
Wang XL, Li ZH, Kong BH, et al. Reduced m6A mRNA methylation is correlated with the progression of human cervical cancer. Oncotarget. 2017;8(58):98918–30.PubMedPubMedCentralCrossRef
46.
Barbieri I, Tzelepis K, Pandolfini L, et al. Promoter- bound METTL3 maintains myeloid leukaemia by m6A-dependent translation control. Nature. 2017;552(7683):126–31.PubMedPubMedCentralCrossRef
47.
Vu LP, Pickering BF, Cheng YM, et al. The N6-methyladenosine (m6A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells. Nat Med. 2017;23(11):1369–76.PubMedPubMedCentralCrossRef
48.
49.
Visvanathan A, Patil V, Arora A, Hegde AS, Arivazhagan A, Santosh V, et al. Essential role of METTL3-mediated m(6)A modification in glioma stem-like cells maintenance and radioresistance. Oncogene. 2018;37:522–33.PubMedCrossRef
50.
Cui Q, Shi HL, Ye P, et al. m6A RNA methylation regulates the Self-renewal and tumorigenesis of glioblastoma stem cells. Cell Rep. 2017;18(11):2622–34.PubMedPubMedCentralCrossRef
51.
Zhang SC, Zhao BS, Zhou AD, et al. m6A demethylase ALKBH5 maintains tumorigenicity of glioblastoma stem-like cells by sustaining FOXM1 expression and cell proliferation program. Cancer Cell. 2017;31(4):591-606.e6.PubMedPubMedCentralCrossRef
52.
Jin D, Guo J, Wu Y, et al. m(6)A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis. Hematol Oncol. 2019;12:135.CrossRef
53.
Liu S, Li Q, Li G, et al. The mechanism of m(6)A methyltransferase METTL3-mediated autophagy in reversing gefitinib resistance in NSCLC cells by beta-elemene. Cell Death Dis. 2020;11:969.PubMedPubMedCentralCrossRef
54.
Ding N, You A, Tian W, et al. Chidamide increases the sensitivity of Non-small Cell Lung Cancer to Crizotinib by decreasing c-MET mRNA methylation. Int J Biol Sci. 2020;16:2595–611.PubMedPubMedCentralCrossRef
55.
56.
Chen MN, Wei L, Law CT, et al. RNA N6-methyladenosine methyl-transferase- like 3 promotes liver cancer progression through YTH-DF2-dependent posttranscriptional silencing of SOCS2. Hepatology. 2018;67(6):2254–70.PubMedCrossRef
57.
Lin Z, Niu Y, Wan A, Chen D, Liang H, Chen X, et al. RNA m(6) A methylation regulates sorafenib resistance in liver cancer through FOXO3-mediated autophagy. EMBO J. 2020;39:e103181.PubMedPubMedCentralCrossRef
58.
Ma JZ, Yang F, Zhou CC, et al. METTL14 suppresses the metastatic potential of hepatocellular carcinoma by modulating N6-methylade-nosine-dependent primary Micro RNA processing. Hepatology. 2017;65(2):529–43.PubMedCrossRef
59.
Yang Z, Li J, Feng GX, et al. MicroRNA-145 modulates N6-methy-ladenosine levels by targeting the 3’- untranslated mRNA region of the N6-methyladenosine binding YTH domain family 2 protein. J Biol Chem. 2017;292(9):3614–23.PubMedPubMedCentralCrossRef
60.
Sun Y, Li S, Yu W, et al. N(6)-methyladenosine-dependent pri-miR-17-92 maturation suppresses PTEN/TMEM127 and promotes sensitivity to everolimus in gastric cancer. Cell Death Dis. 2020;11:836.PubMedPubMedCentralCrossRef
61.
Nishizawa Y, Konno M, Asai A, et al. Oncogene c-Myc promotes epitranscriptome m6A reader YTHDF1 expression in colorectal cancer. Oncotarget. 2018;9(7):7476–86.PubMedCrossRef
62.
Taketo K, Konno M, Asai A, et al. The epitranscriptome m6A writer METTL3 promotes chemo and radioresistance in pancreatic cancer cells. Int J Oncol. 2018;52:621–9.PubMed
63.
Wang S, Sun C, Li J, et al. Roles of RNA methylation by means of N6-methyladenosine (m6A) in human cancers. Cancer Lett. 2017;408:112–20.PubMedCrossRef
64.
Schwartz S, Mumbach MR, Jovanovic M, et al. Perturbation of m6A writers reveals two distinct classes of mRNA methylation at internal and 5’ sites. Cell Rep. 2014;8:284–96.PubMedPubMedCentralCrossRef
Metadata
Title
Recent advances of m6A methylation modification in esophageal squamous cell carcinoma
Authors
Xiaoqing Zhang
Ning Lu
Li Wang
Yixuan Wang
Minna Li
Ying Zhou
Manli Cui
Mingxin Zhang
Lingmin Zhang
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2021
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-021-02132-2

Other articles of this Issue 1/2021

Cancer Cell International 1/2021 Go to the issue

Primary research

Elevation of miR-302b prevents multiple myeloma cell growth and bone destruction by blocking DKK1 secretion

Review

Prognostic significance of the neutrophil-to-lymphocyte ratio in peripheral T-cell lymphoma: a meta-analysis

Primary research

Prognostic and predictive value of FCER1G in glioma outcomes and response to immunotherapy

Primary research

Development and clinical validation of a novel six-gene signature for accurately predicting the recurrence risk of patients with stage II/III colorectal cancer

Primary research

Relationship between PD-L1 expression, CD8+ T-cell infiltration and prognosis in intrahepatic cholangiocarcinoma patients

Primary research

Expression and prognostic significance of CBX2 in colorectal cancer: database mining for CBX family members in malignancies and vitro analyses
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits